A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Aclaris Therapeutics, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -65M | -65M | -132M | -88M | -87M | -91M |
| EPS | $-0.53 | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 |
| Free Cash Flow | -47M | -47M | -20M | -80M | -68M | -52M |
| ROIC | -72.6% | -63.0% | -84.9% | -56.3% | -44.0% | -43.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.56 | 0.42 | 0.26 | 0.29 | 0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -76M | -76M | -142M | -97M | -90M | -90M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -63.0% | -50.2% | -84.9% | -56.3% | -44.0% | -46.0% |
| Shares Outstanding | 122M | 122M | 77M | 70M | 65M | 57M |
Aclaris Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Aclaris Therapeutics, Inc. (ACRS) has a 5-year average return on invested capital (ROIC) of -58.4%. This is below average and may indicate limited pricing power.
Aclaris Therapeutics, Inc. (ACRS) has a market capitalization of $478M. It is classified as a small-cap stock.
Aclaris Therapeutics, Inc. (ACRS) does not currently pay a regular dividend.
Aclaris Therapeutics, Inc. (ACRS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Aclaris Therapeutics, Inc. (ACRS) generated $-47 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Aclaris Therapeutics, Inc. (ACRS) has a debt-to-equity ratio of 0.56. This indicates moderate leverage.
Aclaris Therapeutics, Inc. (ACRS) reported earnings per share (EPS) of $-0.53 in its most recent fiscal year.
Aclaris Therapeutics, Inc. (ACRS) has a return on equity (ROE) of -50.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 10 years of financial data for Aclaris Therapeutics, Inc. (ACRS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aclaris Therapeutics, Inc. (ACRS) has a book value per share of $0.84, based on its most recent annual SEC filing.